title: [Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation].
abstract: Multiple sclerosis (MS) is a chronic autoimmune demyelinating disorder of the central nervous system. Nowadays some disease-modifying drugs (DMD) in the Russian Federation (RF) are biosimilars. Their full spectrum of tolerability and efficacy is to be determined. Here we present results of two retrospective-prospective studies on efficacy and safety of a biosimilar interferon beta-1a (genfaxon) in treatment of MS in the RF.
  
  
  OBJECTIVE
  determination of safety and efficacy profile of genfaxon in a routine neurological practice in the RF.
  
  
  METHODS
  Trials were performed in 18 MS centers in the RF. A total of 649 patients aged from 18 to 68 years with the EDSS score no more than 6.0 were treated with genfaxon for 12 months. The first group was comprised of 'naïve' patients without previous history of DMD administration. There were patients in the second group which have already received some of DMD. Statistical analysis was performed with the help of significance criteria (χ-square), t-criteria of Student for analysis of independent samplings.
  
  
  RESULTS
  There were no serious adverse events during the period of the study. "Naïve" patients had significantly lower number of adverse events, than patients with previous history of DMD usage. Efficacy results were comparable with results published for the Rebif.
  
  
  CONCLUSIONS
  Data, received from the studies show equal efficacy and tolerability of genfaxon compared with original DMD Rebif.
authors.forename: K Z
authors.initials: KZ
authors.lastname: Bakhtiiarova
authors.forename: O V
authors.initials: OV
authors.lastname: Bragina
authors.forename: Ia V
authors.initials: IaV
authors.lastname: Vlasov
authors.forename: I V
authors.initials: IV
authors.lastname: Greshnova
authors.forename: E P
authors.initials: EP
authors.lastname: Evdoshenko
authors.forename: E I
authors.initials: EI
authors.lastname: Ivanishenkova
authors.forename: E I
authors.initials: EI
authors.lastname: Kairbekova
authors.forename: E N
authors.initials: EN
authors.lastname: Karnaukhova
authors.forename: N A
authors.initials: NA
authors.lastname: Korotkevich
authors.forename: A V
authors.initials: AV
authors.lastname: Leliukhina
authors.forename: I S
authors.initials: IS
authors.lastname: Protasov
authors.forename: E V
authors.initials: EV
authors.lastname: Rybina
authors.forename: A I
authors.initials: AI
authors.lastname: Sazhnev
authors.forename: A A
authors.initials: AA
authors.lastname: Skoromets
authors.forename: O A
authors.initials: OA
authors.lastname: Soldatova
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Trinitatskiĭ
authors.forename: A S
authors.initials: AS
authors.lastname: Fedianin
authors.forename: S N
authors.initials: SN
authors.lastname: Chelnokova
authors.forename: V D
authors.initials: VD
authors.lastname: Shabanova
authors.forename: R R
authors.initials: RR
authors.lastname: Sharipova
authors.forename: E A
authors.initials: EA
authors.lastname: Shchegol'kova
authors.forename: I A
authors.initials: IA
authors.lastname: Iampol'skaia-Gosteva
mesh_terms: D000293:Adolescent; D000328:Adult; D059451:Biosimilar Pharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D011446:Prospective Studies; D012189:Retrospective Studies; D012426:Russia; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D059451:Biosimilar Pharmaceuticals; D000068556:Interferon beta-1a